23.34
price up icon4.71%   1.05
after-market Handel nachbörslich: 23.32 -0.02 -0.09%
loading
Schlusskurs vom Vortag:
$22.29
Offen:
$22.48
24-Stunden-Volumen:
4.12M
Relative Volume:
1.15
Marktkapitalisierung:
$17.34B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-746.08M
KGV:
-23.17
EPS:
-1.0074
Netto-Cashflow:
$-211.81M
1W Leistung:
+13.91%
1M Leistung:
+20.03%
6M Leistung:
+40.26%
1J Leistung:
+18.54%
1-Tages-Spanne:
Value
$22.39
$23.58
1-Wochen-Bereich:
Value
$20.48
$23.58
52-Wochen-Spanne:
Value
$15.55
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Firmenname
Summit Therapeutics Inc
Name
Telefon
305-203-2034
Name
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Name
Mitarbeiter
159
Name
Twitter
@summitplc
Name
Nächster Verdiensttermin
2025-08-08
Name
Neueste SEC-Einreichungen
Name
SMMT's Discussions on Twitter

Vergleichen Sie SMMT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SMMT
Summit Therapeutics Inc
23.34 16.56B 220.00K -746.08M -211.81M -1.0074
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.15 105.19B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
450.68 60.24B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.86 61.82B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
798.94 49.09B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
351.09 37.52B 4.56B -176.77M 225.30M -1.7177

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-09-17 Eingeleitet Barclays Underweight
2025-09-04 Eingeleitet Guggenheim Buy
2025-08-19 Eingeleitet Piper Sandler Neutral
2025-07-01 Eingeleitet UBS Buy
2025-06-11 Eingeleitet Leerink Partners Underperform
2025-03-26 Hochstufung Citigroup Neutral → Buy
2025-03-21 Eingeleitet Cantor Fitzgerald Overweight
2025-03-12 Eingeleitet Evercore ISI Outperform
2025-02-28 Eingeleitet Goldman Buy
2025-01-08 Eingeleitet Truist Buy
2024-12-11 Eingeleitet Wells Fargo Overweight
2024-12-06 Eingeleitet Jefferies Buy
2024-11-04 Eingeleitet JMP Securities Mkt Outperform
2024-09-27 Herabstufung Citigroup Buy → Neutral
2024-08-12 Eingeleitet H.C. Wainwright Buy
2024-05-07 Eingeleitet Citigroup Buy
2024-03-26 Eingeleitet Stifel Buy
2018-06-28 Herabstufung Janney Buy → Neutral
2018-05-02 Eingeleitet Janney Buy
2018-04-12 Bestätigt Needham Buy
2018-02-13 Eingeleitet BTIG Research Buy
2018-01-04 Eingeleitet SunTrust Buy
2017-12-01 Fortgesetzt H.C. Wainwright Buy
2016-11-16 Bestätigt RBC Capital Mkts Outperform
2016-10-05 Bestätigt Needham Buy
2016-09-16 Eingeleitet H.C. Wainwright Buy
2015-03-30 Eingeleitet Needham Buy
2015-03-30 Eingeleitet Oppenheimer Outperform
Alle ansehen

Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten

pulisher
Oct 08, 2025

Where is Summit Therapeutics (SMMT) Headed According to Analysts? - Yahoo Finance

Oct 08, 2025
pulisher
Oct 06, 2025

Public Employees Retirement System of Ohio Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

How to use Fibonacci retracement on Summit Therapeutics Inc.Gap Up & Community Verified Trade Signals - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

1 Monster Stock in the Making to Buy and Hold - Yahoo Finance

Oct 05, 2025
pulisher
Oct 05, 2025

Published on: 2025-10-05 07:31:28 - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

How to monitor Summit Therapeutics Inc. with trend dashboards2025 Market Sentiment & Community Driven Trade Alerts - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - Eastern Progress

Oct 03, 2025
pulisher
Oct 03, 2025

How the European Spotlight on Ivonescimab’s Phase III Data Could Shape Summit Therapeutics (SMMT) - simplywall.st

Oct 03, 2025
pulisher
Oct 03, 2025

Is Summit Therapeutics Inc. forming a bottoming baseJuly 2025 Rallies & Real-Time Volume Analysis - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Is Summit Therapeutics Inc. stock supported by strong cash flowsRisk Management & Safe Entry Zone Identification - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance

Oct 02, 2025
pulisher
Oct 02, 2025

H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - MSN

Oct 02, 2025
pulisher
Oct 01, 2025

Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence - Benzinga

Oct 01, 2025
pulisher
Oct 01, 2025

Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo

Oct 01, 2025
pulisher
Oct 01, 2025

Will Summit Therapeutics Inc. stock continue dividend increasesJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com

Oct 01, 2025
pulisher
Oct 01, 2025

Summit Therapeutics (NASDAQ:SMMT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat

Oct 01, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-30 03:00:28 - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-30 00:09:58 - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Will Summit Therapeutics Inc. stock gain from lower inflationWeekly Profit Recap & Pattern Based Trade Signal System - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN

Sep 29, 2025
pulisher
Sep 29, 2025

What analysts say about Summit Therapeutics Inc stockResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in

Sep 29, 2025
pulisher
Sep 27, 2025

Summit Therapeutics Inc Stock Analysis and ForecastAI-Driven Market Analysis & Learn From the Strategies of Institutions - earlytimes.in

Sep 27, 2025
pulisher
Sep 25, 2025

Positive Catalyst Watch Boosts SMMT Stock Outlook - GuruFocus

Sep 25, 2025
pulisher
Sep 25, 2025

Barclays Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Maintains Target Price $13 - 富途牛牛

Sep 25, 2025
pulisher
Sep 24, 2025

Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener

Sep 24, 2025
pulisher
Sep 24, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Sep 24, 2025
pulisher
Sep 24, 2025

First-Ever PD-1 Therapy Superiority: Summit's Ivonescimab Achieves Breakthrough in Advanced Lung Cancer Trial - Stock Titan

Sep 24, 2025
pulisher
Sep 24, 2025

Weekly Analysts’ Ratings Updates for Summit Therapeutics (SMMT) - Defense World

Sep 24, 2025
pulisher
Sep 23, 2025

Voya Investment Management LLC Sells 34,041 Shares of Summit Therapeutics PLC $SMMT - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

Barclays Begins Coverage on Summit Therapeutics (NASDAQ:SMMT) - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire

Sep 22, 2025
pulisher
Sep 22, 2025

Summit Therapeutics Inc. stock chart pattern explainedWeekly Profit Recap & Accurate Intraday Trade Tips - newser.com

Sep 22, 2025
pulisher
Sep 22, 2025

Rockland Trust Co. Takes $8.51 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat

Sep 22, 2025
pulisher
Sep 21, 2025

Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Barclays - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China - MSN

Sep 21, 2025
pulisher
Sep 21, 2025

Wealth Management Partners LLC Sells 20,671 Shares of Summit Therapeutics PLC $SMMT - MarketBeat

Sep 21, 2025
pulisher
Sep 20, 2025

Will Summit Therapeutics Inc. benefit from macro trendsJuly 2025 Fed Impact & High Conviction Investment Ideas - newser.com

Sep 20, 2025
pulisher
Sep 20, 2025

Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright - MarketBeat

Sep 20, 2025

Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$85.38
price down icon 2.05%
$32.74
price up icon 0.31%
$106.28
price up icon 0.21%
$161.81
price down icon 0.31%
biotechnology ONC
$351.09
price up icon 2.77%
Kapitalisierung:     |  Volumen (24h):